Cancer clinical trials: What’s involved for patients?
Summary
Professor Seamus O'Reilly discusses the state of cancer clinical trials in Ireland, highlighting that over 2,000 patients participate annually in studies that often provide earlier access to new treatments. He explains that while trials require significant investment, they generate substantial savings for the state through drug cost offsets and optimized care. O'Reilly advocates for increased government funding to accelerate trial activation and improve patient outcomes, noting that current approval times for new drugs in Ireland are among the lowest in Europe.
Topics discussed
Introduction: Current state of cancer trials in Ireland
Defining clinical cancer trials and types of interventions
How patients access and participate in trials
Public willingness to join trials and patient advocacy
Addressing concerns about treatment quality and ethics
The importance of equipoise, trust, and the COVID example
Patient numbers and historical improvements in survival rates
Funding sources and the case for increased state investment
Economic benefits and cost savings for the state
Urgency of funding versus future government bodies
Drug costs, access to care, and closing remarks
Listen ad-free on Castria